AYTU BIOPHARMA, INC Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
AYTU BIOPHARMA, INC (AYTU) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 4.24 million shares for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-09-22
- AYTU BIOPHARMA, INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 4.25M shares, a 4.01% increase year-over-year.
- AYTU BIOPHARMA, INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-12-31 was 13.52M shares, a 255.45% increase year-over-year.
- AYTU BIOPHARMA, INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 3.89M shares, a 521.12% increase year-over-year.
- AYTU BIOPHARMA, INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 4.08M shares, a 38.73% decline year-over-year.
- AYTU BIOPHARMA, INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2026 was 4.24M shares, a 70.53% decline from fiscal 2025.
- AYTU BIOPHARMA, INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 14.38M shares, a 130.02% increase from fiscal 2024.
- AYTU BIOPHARMA, INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 6.25M shares, a 5.83% decline from fiscal 2023.
- AYTU BIOPHARMA, INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 6.64M shares, a 1147.27% increase from fiscal 2022.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 4.24M shares 10-K · filed 2026-09-22 | |||||||
| 2026-03-31 | 4.25M shares 10-Q · filed 2026-05-13 | 4.72M shares 10-Q · filed 2026-05-13 | ||||||
| 2025-12-31 | 13.52M shares 10-Q · filed 2026-02-03 | 13.77M shares 10-Q · filed 2026-02-03 | ||||||
| 2025-09-30 | 3.89M shares 10-Q · filed 2025-11-13 | |||||||
| 2025-06-30 | 14.38M shares 10-K · filed 2026-09-22 | |||||||
| 2025-03-31 | 4.08M shares 10-Q · filed 2026-05-13 | 3.66M shares 10-Q · filed 2026-05-13 | ||||||
| 2024-12-31 | 3.80M shares 10-Q · filed 2026-02-03 | 3.48M shares 10-Q · filed 2026-02-03 | ||||||
| 2024-09-30 | 626.80K shares 10-Q · filed 2025-11-13 | |||||||
| 2024-06-30 | 6.25M shares 10-K · filed 2025-09-23 | |||||||
| 2024-03-31 | 6.66M shares 10-Q · filed 2025-05-14 | 6.66M shares 10-Q · filed 2025-05-14 | ||||||
| 2023-12-31 | 6.73M shares 10-Q · filed 2025-02-12 | 6.73M shares 10-Q · filed 2025-02-12 | ||||||
| 2023-09-30 | 6.75M shares 10-Q · filed 2024-11-13 | |||||||
| 2023-06-30 | 6.64M shares 10-K · filed 2024-09-26 | |||||||
| 2023-03-31 | 1.79M shares 10-Q · filed 2024-05-15 | |||||||
| 2022-12-31 | 1.81M shares 10-Q · filed 2024-02-14 | |||||||
| 2022-09-30 | 1.78M shares 10-Q · filed 2023-11-14 | 33.53M shares 10-Q · filed 2022-11-14 | ||||||
| 2022-06-30 | 532.10K shares 10-K · filed 2023-10-12 | 10.55M shares 10-K · filed 2022-09-27 | ||||||
| 2022-03-31 | 553.17K shares 10-Q · filed 2023-05-11 | 11.06M shares 10-Q · filed 2022-05-16 | ||||||
| 2021-12-31 | 173.35K shares 10-Q · filed 2023-02-21 | 3.47M shares 10-Q · filed 2022-02-14 | ||||||
| 2021-09-30 | 173.16K shares 10-Q/A · filed 2023-02-21 | 3.46M shares 10-Q · filed 2021-11-15 | ||||||
| 2021-06-30 | 3.42M shares 10-K · filed 2022-09-27 | |||||||
| 2021-03-31 | 1.78M shares 10-Q · filed 2021-05-17 | 1.78M shares 10-Q · filed 2022-05-16 | ||||||
| 2020-12-31 | 3.15M shares 10-Q · filed 2021-02-11 | 2.86M shares 10-Q · filed 2022-02-14 | ||||||
| 2020-09-30 | 2.86M shares 10-Q · filed 2021-11-15 | 28.62M shares 10-Q · filed 2020-11-12 | ||||||
| 2020-06-30 | 2.81M shares 10-K · filed 2021-09-28 | 28.08M shares 10-K · filed 2020-10-06 | ||||||
| 2020-03-31 | 4.47M shares 10-Q · filed 2021-05-17 | 44.72M shares 10-Q · filed 2020-05-15 | ||||||
| 2019-12-31 | 2.20M shares 10-Q · filed 2021-02-11 | 39.98M shares 10-Q · filed 2020-02-14 | ||||||
| 2019-09-30 | 21.95M shares 10-Q · filed 2020-11-12 | |||||||
| 2019-06-30 | 22.63M shares 10-K · filed 2020-10-06 | 22.61M shares 10-K · filed 2019-09-26 | ||||||
| 2019-03-31 | 17.27M shares 10-Q · filed 2020-05-15 | |||||||
| 2018-12-31 | 19.66M shares 10-Q · filed 2020-02-14 | |||||||
| 2018-09-30 | 1.92M shares 10-Q · filed 2019-11-14 | |||||||
| 2018-06-30 | 1.92M shares 10-K · filed 2019-09-26 | |||||||
| 2017-06-30 | 18.37K shares 10-K · filed 2018-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |